Normal delivery following an uneventful pregnancy in a Japanese acromegalic patient after discontinuation of octreotide long acting release formulation at an early phase of pregnancy.
We report a 35-year-old woman with active acromegaly despite pituitary surgery and irradiation who received continuous octreotide LAR treatment for the control of GH excess until discovery of her pregnancy. The patient delivered a healthy boy following an uneventful pregnancy after discontinuing octreotide LAR as soon as possible at the early phase of pregnancy. Despite a substantial maternal-fetal transfer of octreotide, postnatal development was normal at 3 years of age. In almost all previously described cases, octreotide was discontinued after pregnancy was confirmed. No side-effects of mother or fetus have been reported. Octreotide treatment in pregnancy seems to be feasible and safe. Due to the still-limited number of reported cases treated with octreotide LAR, the potential benefits of octreotide LAR treatment should be weighed carefully against its possible risks.
Takano
Tatsuro
T
Department of Medicine, Yokohama Rosai Hospital, Japan.
Saito
Jun
J
Soyama
Akiko
A
Ito
Hiroko
H
Iizuka
Takashi
T
Yoshida
Takao
T
Nishikawa
Tetsuo
T
D000172:Acromegaly / Q000188:drug therapy*; D000328:Adult; D003692:Delayed-Action Preparations / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007564:Japan; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*; D011247:Pregnancy; D011248:Pregnancy Complications; D011256:Pregnancy Outcome; D013995:Time; D028761:Withholding Treatment
D003692:Delayed-Action Preparations; D015282:Octreotide